Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NAVB NASDAQ:NEXI NASDAQ:SYRS NASDAQ:VRPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAVBNavidea Biopharmaceuticals$0.00-80.0%$0.00$0.00▼$0.13$10K1.997,327 shs312 shsNEXINexImmune$0.01$0.00$0.00▼$1.01$14K2.045,993 shsN/ASYRSSyros Pharmaceuticals$0.00+450.0%$0.00$0.00▼$0.10$89K1.31161,929 shs23,136 shsVRPXVirpax Pharmaceuticals$0.01+9.9%$0.08$0.01▼$26.25$14K1.49160,897 shs3,187 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAVBNavidea Biopharmaceuticals-80.00%-80.00%-80.00%-50.00%-90.00%NEXINexImmune0.00%+4,900.00%+4,900.00%+9,900.00%-96.84%SYRSSyros Pharmaceuticals-45.45%-45.45%-62.50%-97.87%-99.97%VRPXVirpax Pharmaceuticals+9.90%0.00%+0.91%-96.02%-99.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAVBNavidea Biopharmaceuticals$0.00-80.0%$0.00$0.00▼$0.13$10K1.997,327 shs312 shsNEXINexImmune$0.01$0.00$0.00▼$1.01$14K2.045,993 shsN/ASYRSSyros Pharmaceuticals$0.00+450.0%$0.00$0.00▼$0.10$89K1.31161,929 shs23,136 shsVRPXVirpax Pharmaceuticals$0.01+9.9%$0.08$0.01▼$26.25$14K1.49160,897 shs3,187 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAVBNavidea Biopharmaceuticals-80.00%-80.00%-80.00%-50.00%-90.00%NEXINexImmune0.00%+4,900.00%+4,900.00%+9,900.00%-96.84%SYRSSyros Pharmaceuticals-45.45%-45.45%-62.50%-97.87%-99.97%VRPXVirpax Pharmaceuticals+9.90%0.00%+0.91%-96.02%-99.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ASYRSSyros Pharmaceuticals 2.00Hold$1.0030,203.03% UpsideVRPXVirpax Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNAVBNavidea Biopharmaceuticals$8.13K1.23N/AN/AN/A∞NEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ASYRSSyros Pharmaceuticals$386K0.23N/AN/A$0.79 per share0.00VRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/A∞N/AN/A-534.32%-213.72%N/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2025 (Estimated)VRPXVirpax Pharmaceuticals-$15.19MN/A0.00∞N/AN/A-1,554.34%-338.29%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNAVBNavidea BiopharmaceuticalsN/AN/AN/ANEXINexImmuneN/A0.660.66SYRSSyros PharmaceuticalsN/A2.252.25VRPXVirpax PharmaceuticalsN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNAVBNavidea Biopharmaceuticals0.01%NEXINexImmune9.85%SYRSSyros Pharmaceuticals91.47%VRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipNAVBNavidea Biopharmaceuticals43.68%NEXINexImmune14.90%SYRSSyros Pharmaceuticals12.26%VRPXVirpax Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableNEXINexImmune701.40 million1.19 millionNot OptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionOptionableVRPXVirpax Pharmaceuticals71.24 million4.71 millionNot OptionableNAVB, SYRS, NEXI, and VRPX HeadlinesRecent News About These CompaniesVirpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comVirpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comVirpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using METMarch 11, 2025 | msn.comVirpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology ConferenceMarch 11, 2025 | msn.comVirpax Looking to Use MET to Develop Intranasal COVID VaccineMarch 7, 2025 | businesswire.comAnalysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)March 6, 2025 | markets.businessinsider.comVirpax’s NES100 to be Presented at The Society of Toxicology by NCATSMarch 5, 2025 | finance.yahoo.comVirpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope TechnologyMarch 3, 2025 | msn.comVirpax lauds Nanomerics’ MET study with no severe side effectsMarch 1, 2025 | investing.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | finance.yahoo.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | businesswire.comVirpax Confirms Positive Results with US Army with Probudur™ for Combat Care StudyFebruary 13, 2025 | joplinglobe.comJVirpax Pharmaceuticals confirms results with U.S. Army with ProbudurFebruary 13, 2025 | markets.businessinsider.comVirpax reports positive study results for pain management drugFebruary 13, 2025 | msn.comVirpax Pharmaceuticals appoints new independent directorFebruary 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAVB, SYRS, NEXI, and VRPX Company DescriptionsNavidea Biopharmaceuticals NYSE:NAVB$0.0001 0.00 (-80.00%) As of 03:03 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.NexImmune NASDAQ:NEXI$0.01 0.00 (0.00%) As of 09/16/2025NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Syros Pharmaceuticals NASDAQ:SYRS$0.0033 +0.00 (+450.00%) As of 02:04 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Virpax Pharmaceuticals NASDAQ:VRPX$0.01 +0.00 (+9.90%) As of 09/16/2025 12:26 PM EasternVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
